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Abstract 
 
Background  
Several sex differences in schizophrenia have been reported including differences in 
cognitive functioning. Studies with schizophrenia patients and healthy controls (HC) indicate 
that the sex advantage for women in verbal domains is also present in schizophrenia 
patients. However, findings have been inconsistent. No study has yet analysed sex-related 
cognitive performance differences in at-risk mental state for psychosis (ARMS) individuals. 
Thus, the aim of the present study was to investigate sex differences in cognitive functioning 
in ARMS, first episode psychosis (FEP) and HC subjects. We expected a better verbal 
learning and memory performance of women in all groups.  
 
Methods  
The neuropsychological data analysed in this study were collected within the prospective 
Früherkennung von Psychosen (FePsy) study. In total, 118 ARMS, 88 FEP individuals and 
86 HC completed a cognitive test battery covering the domains of executive functions, 
attention, working memory, verbal learning and memory, IQ and speed of processing.  
 
Results 
Women performed better in verbal learning and memory regardless of diagnostic group. By 
contrast, men as compared to women showed a shorter reaction time during the working 
memory task across all groups.  
 
Conclusion 
The results provide evidence that women generally perform better in verbal learning and 
memory, independent of diagnostic group (ARMS, FEP, HC). The finding of a shorter 
reaction time for men in the working memory task could indicate that men have a superior 
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working memory performance since they responded faster during the target trials, while 
maintaining a comparable overall working memory performance level. 
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1. Introduction 
Sex differences in schizophrenia are described in almost all aspects of the illness, 
including age of onset, symptomatology, treatment response, time course and psychosocial 
outcome [1-3]. One of the most consistent findings is that women are older than men when 
first symptoms arise [4, 5]. Furthermore, women – especially at younger ages – seem to 
have a more favourable outcome than men [2, 6]. 
Closely related to the outcome of the disease is the impairment of cognitive functioning which 
is recognized as a core feature of schizophrenia [7, 8] that is not only present in patients with 
schizophrenic psychoses, but already evident in individuals with an at-risk mental state 
(ARMS) for psychosis [9-11]. In addition, it has been shown that ARMS individuals with later 
transition to psychosis perform worse on tests measuring verbal fluency and memory [9, 12] 
and speed of information processing [13, 14] compared to those without transition. It has 
been consistently reported that prediction of psychosis can be improved by considering 
neurocognitive performance measures [14, 15]. However, deficits in specific cognitive 
domains among ARMS and schizophrenia patients are at least in part explained by 
differences in IQ [Referenz einfügen]. 
Sex differences in cognitive functioning are well known in healthy individuals. In general, 
women tend to perform better than men in tasks measuring verbal abilities, whereas the 
opposite is true for visuospatial skills [16-19]. Kimura suggested that tasks measuring verbal 
memory account for the most prominent sex differences [20]. 
Differences in cognitive functioning between men and women have also been reported in 
schizophrenia patients. Many studies have shown that women with schizophrenia perform 
better than men with schizophrenia in the domain of verbal learning and memory [21-28] 
which is in line with findings in healthy controls (HC). In other cognitive domains, however, 
results have been largely heterogeneous. In the domain of executive functions, two studies 
have demonstrated that women with schizophrenia perform better as compared to men with 
schizophrenia [21, 29], two studies showed a worse performance of female patients as 
compared to male patients [22, 30] and three studies did not find any performance 
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differences [24, 25, 31]. In the domain of attention, two studies showed a better performance 
of women in relation to men with schizophrenia [21, 28], one showed a worse performance of 
female patients [32] and five studies could not detect any sex differences [23-26, 33]. With 
regard to working memory, one study found that women with schizophrenia perform worse, 
while three studies did not detect any performance differences. Interestingly, when 
comparing clinical with healthy control samples, Longenecker et al. reported an interaction 
effect in the working memory domain: Men with schizophrenia failed to exhibit the sex 
advantage during a working memory task which was evident in the healthy control sample 
[27]. In relation to IQ estimates, three studies out of four showed an equal performance for 
both sexes of schizophrenia patients [25, 33, 34]. For speed of processing, there is one study 
which showed a better performance for women [23] and one study which depicted no sex 
difference in schizophrenia patients [24].  
Since cognitive impairment is recognized as a core feature of schizophrenia, sex differences 
in cognitive functioning could contribute to explaining pathogenic mechanisms of the illness. 
However, most of the above named studies were conducted in chronic and/or medicated 
patients whose neurocognitive performance might thus have been influenced by the effects 
of medication or chronicity. No study has yet analysed sex-related cognitive performance 
differences in ARMS individuals and first episode psychosis (FEP) patients. Thus, the aim of 
the present study was to investigate sex differences in cognitive functioning in ARMS, FEP 
and HC subjects and whether sex differences vary between the examined groups. Based on 
the above cited studies, we expected a better performance of women in the domain of verbal 
learning and memory in all groups. 
 
2. Methods 
Setting and recruitment 
The neuropsychological data analysed in this study were collected within the prospective 
Früherkennung von Psychosen (FePsy) study, which aims to improve the early detection of 
psychosis. A more detailed description of the overall study design can be found elsewhere 
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[35, 36]. Participants were recruited for the study via the FePsy Clinic at the Psychiatric 
University Outpatient Department of the Psychiatric University Clinics Basel, which was set 
up specifically to identify and treat individuals in the early stages of psychosis.  
We recruited a sample of HC from trade schools, hospital staff and through advertisements. 
HC subjects with a current or former psychiatric disorder or neurological disease, serious 
medical condition, substance abuse, or a family history of psychiatric disorder were 
excluded.  
The study was approved by the ethics committee of the University of Basel and all 
participants provided written informed consent. 
 
Screening procedure 
Screening was performed with the Basel Screening Instrument for Psychosis [37]. This 
instrument allows the rating of individuals regarding the inclusion/exclusion criteria 
corresponding to the Personal Assessment and Crisis Evaluation (PACE) criteria [38, 39] 
and has been shown to have a good interrater reliability (κ=0.67) for the assessment of the 
main outcome category “at risk for psychosis” and a high predictive validity [37]. Individuals 
were classified as being in an ARMS for psychosis, having a FEP, or being not at risk for 
psychosis (usually other psychiatric disorders). We included ARMS, FEP as well as a sample 
of HC in the present study. 
 
Neuropsychological assessment 
All neuropsychological assessments were conducted by psychologists and well-trained, 
supervised advanced psychology students. The test battery covered the following domains: 
general intelligence, executive functions, working memory, attention, verbal learning and 
memory [35, 36]. 
General intelligence was estimated with the Mehrfachwahl-Wortschatz Test (MWT-A)[40] 
and the Leistungsprüfsystem, scale 3 [41], which are well established German intelligence 
scales for assessing verbal and nonverbal (abstract reasoning) abilities.  
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Executive functions were assessed with the Tower of Hanoi (ToH) [42], Wisconsin Card 
Sorting Test (WCS) [43, 44], and Go/No-Go subtest of the Test of Attentional Performance 
(TAP) [45]. 
Working memory was measured with the 2-back task of the TAP [45] and vigilance with the 
Continuous Performance Test (CPT-OX) [46]. 
Verbal learning and memory were assessed with the California Verbal Learning Test (CVLT) 
[47]. 
For the Go/No-Go subtest and the 2-back task of the TAP as well as for the CPT-OX Test 
that requires subjects to discriminate between two possible stimuli, we used the Signal 
Detection Theory (SDT) to measure performance in terms of “response bias” and 
“sensitivity”. Response bias reflects the tendency to respond with yes and was quantified by 
the measure c, whereas sensitivity indicates the degree of overlap between the signal and 
the noise distributions and was quantified by the measure d’. Both measures were calculated 
according to the formulas provided in Wright [48] using the R package sdtalt [48]. The main 
advantage of using SDT measures is the separation of response bias and sensitivity [49]. 
A summary cognitive score was calculated by performing a principal component analysis on 
the test scores of the above described tasks and extracting the factor scores of the first 
principal component. Thus, test scores were integrated in the summary score with different 
weights, depending on how much they loaded on the first principal component. The first 
principal component explained 22% of the total variance. 
 
Psychopathological assessments 
Positive psychotic symptoms (i.e., hallucinations, suspiciousness, unusual thought 
content and conceptual disorganisation) were assessed with the Brief Psychiatric Rating 
Scale (BPRS) [50, 51] and negative symptoms with the Scale for the Assessment of 
Negative Symptoms (SANS) [52]. 
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Statistical analyses 
All data were analysed using the R environment for statistical computing [53]. Differences 
in sociodemographic and clinical characteristics between men and women within each 
diagnostic group (ARMS, FEP, HC and total group) were tested with t and χ2 tests.  
The following procedure was applied to investigate the effects of sex (men, women) and 
diagnostic group (ARMS, FEP, HC) on cognitive functioning. All of the 25 dependant 
variables, reflecting cognitive functioning were screened for outliers. Values that were 3 
standard deviations above or below the mean were treated as missing if they could be 
attributed to misunderstanding of instructions or truncated (i.e., replaced by the mean ± 3 
standard deviations) if no obvious cause for their emergence could be found. The Box-Cox 
transformation [54] was applied to the outcome measures which did not conform to 
assumptions of normality and/or homogeneity of variance. The Box-Cox procedure 
automatically selects exponential transformations that are optimal with regard to normalizing 
distributions and equalizing variances (Supplementary Table 1). 
Since some of the outcome measures contained missing data (Supplementary Table 1), we 
next performed multiple imputation (MI) using the Multivariate Imputation by Chained 
Equations software [55]. MI is considered the method of choice of handling complex 
incomplete data problems because it yields unbiased parameter estimates and standard 
errors under a missing at random (MAR) or missing completely at random (MCAR) missing 
data mechanism and maximizes statistical power by using all available information [56]. 
We generated 100 imputations of the missing values such that 100 completed datasets were 
obtained to protect against a potential power falloff from a too small number of imputations 
[57]. The analyses of interest were then conducted in each completed data set and 
parameter estimates were pooled according to Rubin’s rules [58].  
Analyses of covariance models (ANCOVA) were applied to evaluate the main effects of sex 
and group (ARMS, FEP, HC) as well as their interactions on cognitive functioning. We 
included sex and diagnostic group (ARMS, FEP, HC) as between subject factors and 
influence of age, years of education and use of antipsychotics as covariates. In case of 
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significant interaction between sex and diagnostic group, sex differences were explored 
within each diagnostic group separately. The results are presented with and also without 
correction for multiple testing. Each table contains a column with the uncorrected and a 
column with the corrected p–values (Benjamini and Hochberg correction) [59]. 
 
3. Results 
Sample description 
136 ARMS individuals and 104 FEP patients were recruited for the FePsy study from 
March 1, 2000 to November 1, 2013. We also recruited a sample of 97 HC participants. We 
excluded 18 ARMS, 16 FEP and 11 HC because their cognitive performance measures were 
not assessed.  
Thus, we performed the analysis on the remaining sample consisting of 118 ARMS, 88 FEP 
and 86 HC subjects. The excluded individuals did not differ from the included ones with 
regard to sex, age, years of education, BPRS total score, BPRS Psychosis/Thought 
Disturbance [49] and SANS total score. Sociodemographic as well as clinical characteristics 
of the included individuals are presented in Table 1. There were no sex differences in ARMS, 
FEP, HC and in the total group with regard to age, years of education, use of antipsychotics, 
BPRS total score and SANS total score except for more pronounced Psychosis/Thought 
Disturbance of women in the total group (ARMS + FEP) and an older age of women in the 
HC group.  
 
Insert Table 1 about here 
 
Effects of sex and diagnostic group on cognitive functioning 
Sex differences between men and women in the total group as well as within each 
diagnostic group separately for each cognitive performance measure are displayed in Figure 
1. In the ANCOVA model used, diagnostic group (ARMS, FEP, HC) and sex served as 
between subject factors with age, years of education and use of antipsychotics being 
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selected as covariates. There was one significant interaction effect in verbal IQ (p = 0.028) 
(Table 2) which was due to a non-significantly worse performance of women in the ARMS (d 
= -0.286) (Supplementary Table 2) and FEP group (d = -0.168) (Supplementary Table 3) and 
a non-significantly better performance in the HC group (d = 0.177) (Supplementary Table 4). 
However, this interaction was no longer significant after correction for multiple testing. 
 
Insert Figure 1 about here 
Insert Table 2 about here 
 
Effects of diagnostic group are presented in Table 2 and have already been described 
previously [60]. We will not describe this aspect any further because it is not the focal point of 
the present study.  
In the total group (ARMS+FEP+HC), women remembered more words in the CVLT trials 1-5 
(p = 0.046, d = 0.258) (Table 2, Supplementary Table 5) and showed less retroactive 
interference (i.e., influence of newly learned words on the recall of previously learned words) 
(p = 0.048, d = 0.270) (Table 2, Supplementary Table 5). By contrast, in the total group men 
demonstrated a shorter working memory reaction time (p = 0.046, d = -0.236) (Table 2, 
Supplementary Table 5). However, all these significant sex differences did not withstand 
correction for multiple testing. 
Considering each group separately there were no sex differences in ARMS and FEP 
(Supplementary Table 2 and Supplementary Table 3). In the group of HC, there was only 
one significant sex difference. Specifically, men demonstrated less response bias in the 
Go/NoGo task (p = 0.011, d = -0.352) (Supplementary Table 4), but only if uncorrected for 
multiple testing. 
 
4. Discussion 
To the best of our knowledge, this is the first study investigating sex-related 
neurocognitive performance differences in a sample of HC, ARMS and FEP patients. In line 
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with our hypothesis, we found that women perform better in the domain of verbal learning 
and memory independent of diagnostic group. Furthermore, men as compared to women 
showed a shorter reaction time in the working memory task. Additionally, we found a sex × 
group interaction effect on verbal IQ, which was due to a non-significantly worse 
performance of women in the ARMS and FEP group and a non-significantly better 
performance in the HC group. All these results, however, did not withstand correction for 
multiple testing. Given that sex-related cognitive performance differences have been found to 
be rather small [61], we decided to discuss findings that were only significant at an 
uncorrected level to account for potential false negative results.  
Our finding that women perform better in the domain of verbal learning and memory across 
all diagnostic groups is consistent with a large body of evidence [16, 24, 27, 62, 63]. Since 
we did not find an interaction between diagnostic group and verbal learning and memory, our 
results suggest that the sex advantage of women in verbal learning and memory is equally 
present in ARMS as in FEP and HC individuals. As previous studies did not compare ARMS 
with HC and FEP individuals, this has not been demonstrated previously. Unexpectedly, we 
found that men had a shorter reaction time in the 2-back task than women independent of 
diagnostic group. This could indicate that men have a superior working memory performance 
since they responded faster during the target trials, while maintaining a comparable overall 
performance level. This result cannot be better explained by a generally enhanced 
processing speed as no sex differences in reaction time during CPT and Go/NoGo were 
detected. Our finding of a significant sex × group interaction in verbal IQ is difficult to explain 
as it is not substantiated by the literature. One potential explanation for a worse performance 
of women in the ARMS and FEP group could be that women in our sample have more 
severe positive symptoms than men as indicated by the BPRS psychosis/thought 
disturbance dimension score. However, an association between positive symptoms and 
verbal IQ has not been established in the literature and only appears to exist for negative and 
disorganised symptom dimensions [64, 65]. 
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Some earlier studies [33, 66], which did not detect any sex differences in cognitive 
functioning were conducted in chronic schizophrenia patients who were seriously impaired 
and therefore represented a different patient population. It is conceivable that sex differences 
at a very low level of functioning do not exist or that they could not be detected because of 
floor effects. In the present study, we included mainly antipsychotic naïve ARMS and FEP 
individuals and therefore it should be noticed that our sample is not comparable to chronic 
schizophrenia patients. The following limitations should be taken into account: Our 
neuropsychological tasks were originally selected to assess the risk of psychosis and not 
specifically to detect sex differences. Therefore, our test battery did not include some of the 
most sensitive tasks to detect sex differences such as visuo-spatial or mental rotation tasks. 
Furthermore, meta-analyses suggest that sex-related cognitive performance differences are 
rather small [61]. Hence, our modest sample size could have precluded the detection of 
some sex effects. Another important aspect to consider is the conceptual difference of 
gender and sex. While gender refers to masculinity/femininity rooted in sociocultural 
descriptions (measured by a questionnaire), sex is a biologically reduced and dichotomous 
term. Lewine et al. [67] reported results that indicate stronger gender than sex effects. 
Accordingly, in this paper we used the term sex because we did not evaluate gender. Finally, 
it should be noted that neuropsychological performance in women has been shown to 
fluctuate with their monthly cycle [68-71] which we did not control in this study. High levels of 
ovarian hormones in the midluteal phase may facilitate certain skills that show a female 
advantage, while being detrimental to skills that normally show a male advantage [69]. Thus, 
it is possible that some effects would have been more pronounced if we had measured 
women at a specific point during their monthly cycle.  
Taken together, our results suggest that sex differences in cognitive functioning in ARMS 
and FEP patients are not different from those seen in HC. Specifically, the female advantage 
in verbal learning and memory which has frequently been found in HC seems equally present 
in ARMS and FEP patients. Future studies should also consider menstrual status in women 
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as well as making a distinction between gender and sex to identify potential differences in 
cognitive functioning. 
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Table 1: Sample description 
 Total group  ARMS  FEP  HC 
 Men Women 
p-value N 
 Men Women 
p-value 
 Men Women 
p-value 
 Men Women 
p-value 
 N=174 N=118  N=73 N=45  N=56 N=32  N=45 N=41 
Age 26.2 (6.67) 27.7 (8.92) 0.133 292  25.6 (6.36) 27.2 (9.67) 0.326  29.2 (7.35) 30.3 (10.4) 0.579  23.6 (4.77) 26.2 (6.22) 0.038* 
Years of education 11.7 (2.99) 12.1 (3.04) 0.316 292  11.8 (3.04) 11.8 (3.00) 0.997  11.3 (3.08) 11.4 (3.12) 0.826  12.3 (2.74) 13.0 (2.87) 0.244 
Antipsychotics currently:   0.989 290    0.150    0.770    1.000 
    no 148 (85.5%) 101 (86.3%)    70 (95.9%) 39 (88.6%)   33 (60.0%) 21 (65.6%)   45 (100%) 41 (100%)  
    yes 25 (14.5%) 16 (13.7%)    3 (4.11%) 5 (11.4%)   22 (40.0%) 11 (34.4%)   0 (0.00%) 0 (0.00%)  
Chlorpromazine equivalent dose [mg] 221 (179) 204 (141) 0.735 40  217 (76.4) 245 (155) 0.742  222 (190) 185 (138) 0.538  . .  
Antipsychotics compound:   0.123 290    0.198    0.124    1.000 
    none 148 (85.5%) 101 (86.3%)    70 (95.9%) 39 (88.6%)   33 (60.0%) 21 (65.6%)   45 (100%) 41 (100%)  
    Aripiprazole 0 (0.00%) 2 (1.71%)    0 (0.00%) 0 (0.00%)   0 (0.00%) 2 (6.25%)   0 (0.00%) 0 (0.00%)  
    Risperidone 6 (3.47%) 8 (6.84%)    1 (1.37%) 3 (6.82%)   5 (9.09%) 5 (15.6%)   0 (0.00%) 0 (0.00%)  
    Quetiapine 6 (3.47%) 2 (1.71%)    0 (0.00%) 0 (0.00%)   6 (10.9%) 2 (6.25%)   0 (0.00%) 0 (0.00%)  
    Olanzapine 13 (7.51%) 4 (3.42%)    2 (2.74%) 2 (4.55%)   11 (20.0%) 2 (6.25%)   0 (0.00%) 0 (0.00%)  
Antidepressants currently:   0.692 290    0.854    0.694    1.000 
    no 139 (80.3%) 97 (82.9%)    49 (67.1%) 28 (63.6%)   45 (81.8%) 28 (87.5%)   45 (100%) 41 (100%)  
    yes 34 (19.7%) 20 (17.1%)    24 (32.9%) 16 (36.4%)   10 (18.2%) 4 (12.5%)   0 (0.00%) 0 (0.00%)  
Tranquilizer currently:   0.525 290    0.242    0.835    1.000 
    no 148 (85.5%) 96 (82.1%)    61 (83.6%) 32 (72.7%)   42 (76.4%) 23 (71.9%)   45 (100%) 41 (100%)  
    yes 25 (14.5%) 21 (17.9%)    12 (16.4%) 12 (27.3%)   13 (23.6%) 9 (28.1%)   0 (0.00%) 0 (0.00%)  
BPRS total score 43.2 (11.7) 45.7 (12.7) 0.191 175  38.7 (9.57) 41.0 (10.7) 0.265  50.0 (11.4) 52.2 (12.6) 0.449  . .  
BPRS Psychosis/Thought Disturbance 7.85 (3.64) 9.10 (4.21) 0.045* 178  5.92 (2.29) 6.93 (3.02) 0.072  10.8 (3.33) 12.3 (3.67) 0.093  . .  
SANS total score 24.8 (16.3) 21.2 (15.7) 0.166 155  25.3 (17.6) 18.9 (16.3) 0.084  24.2 (14.8) 24.2 (14.7) 0.992  . .  
ARMS = at-risk mental state; FEP = first episode psychosis; HC = healthy controls; BPRS = Brief psychiatric rating scale; SANS = Scale for the assessment of negative symptoms; *  p < 0.05 
Regarding psychopathological measures (BPRS and SANS) the total group consists of ARMS + FEP (without the HC’s); continuous variables are described by means and standard deviation in brackets 
 
Table 2: P-values of ANCOVAs with ARMS, FEP and HC 
 uncorrected corrected 
 group     sex group x sex     group    sex group x sex 
IQ       
   Nonverbal IQ <0.001*** 0.516 0.797   0.002** 0.777 0.945 
   Verbal IQ   0.014 0.308 0.028*   0.033* 0.665 0.739 
Executive Functions       
   ToH total time   0.006** 0.192 0.650   0.016* 0.665 0.945 
   ToH 4 and 5 disc moves   0.015* 0.344 0.916   0.034* 0.665 0.945 
   WCS total assignments   0.002** 0.496 0.921   0.011* 0.777 0.945 
   WCS perseveration score   0.059 0.272 0.558   0.101 0.665 0.945 
   Go/NoGo reaction time   0.003** 0.530 0.634   0.013 0.777 0.945 
   Go/NoGo c (response bias)   0.238 0.580 0.505   0.310 0.777 0.945 
   Go/NoGo d’ (sensitivity)   0.170 0.877 0.763   0.237 0.908 0.945 
Attention & Working Memory       
   WM reaction time <0.001*** 0.046* 0.639 <0.001*** 0.413 0.945 
   WM c (response bias)   0.005** 0.358 0.103   0.015* 0.665 0.945 
   WM d’ (sensitivity)   0.001** 0.239 0.290   0.008** 0.665 0.945 
   CPT reaction time   0.004** 0.212 0.821   0.013* 0.665 0.945 
   CPT slowing   0.173 0.141 0.913   0.237 0.665 0.945 
   CPT c (response bias)   0.061 0.627 0.334   0.101 0.777 0.945 
   CPT d’ (sensitivity)   0.019* 0.326 0.410   0.038* 0.665 0.945 
Verbal learning & Memory       
   CVLT total correct trial 1-5   0.012* 0.046* 0.938   0.031* 0.413 0.945 
   CVLT long delay free recall   0.062 0.098 0.859   0.101 0.634 0.945 
   CVLT Semantic cluster ratio   0.267 0.241 0.624   0.316 0.665 0.945 
   CVLT Serial cluster ratio   0.324 0.522 0.279   0.367 0.777 0.945 
   CVLT Percent primacy recall   0.746 0.636 0.660   0.775 0.777 0.945 
   CVLT Percent middle recall   0.256 0.716 0.767   0.316 0.810 0.945 
   CVLT Percent recency recall   0.579 0.908 0.945   0.627 0.908 0.945 
   CVLT proactive interference   0.101 0.870 0.890   0.155 0.908 0.945 
   CVLT retroactive interference   0.920 0.048* 0.362   0.920 0.413 0.945 
Composite       
   Total score <0.001*** 0.658 0.886 <0.001*** 0.777 0.945 
 
ARMS = at-risk mental state; FEP = first episode psychosis; HC = healthy controls; ToH = Tower of Hanoi; WCS = Wisconsin 
Card Sorting Test; CPT = Continuous performance Task; CVLT = California Verbal Learning Task; * p < 0.05; ** p < 0.01; *** p 
< 0.001 
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Figure Legend 
 
Figure 1. Cognitive performance of women compared to men in at-risk mental state (ARMS) for psychosis individuals, first 
episode psychosis (FEP) patients, healthy controls (HC) and in the total group. The dotted horizontal line at zero represents the 
performance of men. Differences are expressed in units of Cohen’s d and are significant if the 95% confidence interval (vertical 
line) does not overlap with zero. Variables with a minus sign were reversed so that positive scores always represent good 
performance. Differences are adjusted for the influence of age, years of education and use of antipsychotics. In the total group, 
we additionally corrected for diagnostic group. 
ARMS = at risk mental state; FEP = First episode psychosis; HC = Healty controls; total = ARMS +FEP + HC; ToH = Tower of 
Hanoi; WCS = Wisconsin Card Sorting Test; CPT = Continuous performance Task; CVLT = California Verbal Learning Task. 
 
